ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,003,779,130 | +0.2% | 10,719,555 | -4.5% | 19.76% | +4.5% |
Q2 2023 | $1,001,863,112 | +34.3% | 11,225,357 | +61.3% | 18.92% | +12.0% |
Q1 2023 | $745,948,732 | -12.2% | 6,957,179 | 0.0% | 16.89% | -2.0% |
Q4 2022 | $849,680,271 | +8.7% | 6,957,179 | -8.1% | 17.23% | +3.4% |
Q3 2022 | $781,462,000 | +11.1% | 7,567,900 | 0.0% | 16.67% | -11.1% |
Q2 2022 | $703,512,000 | -20.8% | 7,567,900 | 0.0% | 18.76% | -3.2% |
Q1 2022 | $888,169,000 | -12.8% | 7,567,900 | 0.0% | 19.38% | +8.0% |
Q4 2021 | $1,018,110,000 | -13.5% | 7,567,900 | +2.4% | 17.95% | +10.0% |
Q3 2021 | $1,177,557,000 | +31.5% | 7,387,900 | +8.5% | 16.32% | +13.5% |
Q2 2021 | $895,374,000 | +8.3% | 6,806,341 | +6.1% | 14.37% | +15.3% |
Q1 2021 | $826,408,000 | -15.5% | 6,412,228 | +9.3% | 12.46% | -8.9% |
Q4 2020 | $978,221,000 | +7.3% | 5,865,338 | -0.8% | 13.68% | -18.0% |
Q3 2020 | $911,991,000 | +25.5% | 5,909,742 | +20.2% | 16.68% | +17.8% |
Q2 2020 | $726,922,000 | +31.3% | 4,914,955 | 0.0% | 14.16% | -19.0% |
Q1 2020 | $553,473,000 | -4.9% | 4,914,955 | +17.4% | 17.48% | -1.0% |
Q4 2019 | $582,265,000 | +46.3% | 4,185,342 | +1.3% | 17.66% | -25.5% |
Q3 2019 | $398,037,000 | -16.4% | 4,132,442 | 0.0% | 23.72% | -7.2% |
Q2 2019 | $475,851,000 | -2.2% | 4,132,442 | 0.0% | 25.54% | +21.8% |
Q1 2019 | $486,388,000 | +83.1% | 4,132,442 | -2.5% | 20.97% | +35.6% |
Q4 2018 | $265,670,000 | -11.6% | 4,240,536 | 0.0% | 15.46% | -3.7% |
Q3 2018 | $300,484,000 | +6.5% | 4,240,536 | 0.0% | 16.06% | -12.3% |
Q2 2018 | $282,080,000 | +1.7% | 4,240,536 | 0.0% | 18.31% | -13.8% |
Q1 2018 | $277,331,000 | +24.1% | 4,240,536 | -24.0% | 21.25% | +13.6% |
Q4 2017 | $223,562,000 | +10.5% | 5,580,690 | 0.0% | 18.71% | +2.4% |
Q3 2017 | $202,300,000 | +30.6% | 5,580,690 | 0.0% | 18.28% | +2.8% |
Q2 2017 | $154,920,000 | +2.3% | 5,580,690 | +3.2% | 17.78% | -4.3% |
Q1 2017 | $151,480,000 | +38.3% | 5,409,990 | 0.0% | 18.58% | +19.8% |
Q4 2016 | $109,498,000 | +48.0% | 5,409,990 | +47.0% | 15.51% | +103.2% |
Q3 2016 | $73,998,000 | +63.4% | 3,681,491 | +7.9% | 7.63% | +21.7% |
Q2 2016 | $45,289,000 | +13.0% | 3,412,857 | +57.9% | 6.27% | +22.4% |
Q1 2016 | $40,093,000 | +30.9% | 2,161,366 | +29.3% | 5.12% | +69.1% |
Q4 2015 | $30,621,000 | +18.4% | 1,671,447 | +14.4% | 3.03% | -18.4% |
Q3 2015 | $25,864,000 | -23.5% | 1,461,268 | -23.6% | 3.71% | +9.1% |
Q2 2015 | $33,825,000 | +90.5% | 1,913,153 | +86.9% | 3.40% | +92.9% |
Q1 2015 | $17,760,000 | – | 1,023,652 | – | 1.76% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |